bp1.4979
Small moleculeexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2013 (NCT01785147)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Dopamine D3 receptorPARTIAL AGONIST
DRD3 partial agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bp1.4979
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07047404 | Phase 2 | Sep 15, 2025 | Bioprojet, University of Nimes |
| NCT07074002 | Phase 2 | Jul 31, 2025 | Bioprojet, University of Lille |
| NCT05118906 | Phase 2 | Dec 31, 2021 | Bioprojet, Sorbonne University |
| NCT03345953 | Phase 2 | Feb 6, 2018 | Bioprojet, Hôpital Pellegrin, Bordeaux, FRANCE |
| NCT01785147 | Phase 2 | Feb 1, 2013 | Bioprojet |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bioprojet | For profit | 5 | 5 | 1 | 2013 |
| Hôpital Pellegrin, Bordeaux, FRANCE | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Sorbonne University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Lille | Academic/Hospital | 1 | 0 | 1 | 2025 |
| University of Nimes | Academic/Hospital | 1 | 0 | 1 | 2025 |
5 organizations
Page 1 / 1